Medical Equipment

Uterine Fibroid Embolization Device Market Size Outlook and Demand Growth Across 2026–2030

March 17, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Uterine Fibroid Embolization Device Market Over The Period 2026–2030?

The market for uterine fibroid embolization devices has observed consistent growth recently. It is forecast to increase from $5.93 billion in 2025 to $6.19 billion in 2026, progressing at a compound annual growth rate (CAGR) of 4.4%. The expansion witnessed in prior periods can be attributed to the rising occurrence of uterine fibroids in women of reproductive age, an increasing volume of gynecological procedures conducted in hospitals and clinics, the growing utilization of uterine artery embolization in interventional radiology, improved public understanding of alternatives to open surgical myomectomy, and the expansion of minimally invasive treatment approaches in specialized medical centers.

The uterine fibroid embolization device market size is anticipated to experience consistent expansion over the upcoming years. It is projected to reach $7.33 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. This growth during the forecast period can be ascribed to several factors, including an escalating demand for uterus-sparing fibroid therapies among younger patients, an expanding clinical preference for minimally invasive and non-invasive treatment approaches, a surge in procedural adoption within ambulatory surgical centers, the broadened application of ablation and embolization devices to reduce fibroid size, and increased investments in sophisticated delivery catheters and embolic systems to enhance treatment accuracy. Key trends during this period encompass the increasing embrace of minimally invasive embolization methods for addressing uterine fibroids, a growing clinical leaning towards organ-preserving options instead of hysterectomy, the greater deployment of image-guided interventional devices for focused fibroid treatment, the wider application of embolization procedures in outpatient and ambulatory surgical environments, and an escalating need for precise delivery systems to enhance safety and results of procedures.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp

Which Economic Or Industry Drivers Are Impacting The Uterine Fibroid Embolization Device Market?

The increasing requirement for minimally invasive surgical procedures is anticipated to fuel the expansion of the uterine fibroid embolization device market in the future. These surgeries involve surgical techniques that utilize small cuts or existing body orifices to reach and manage internal structures, organs, or tissues, thereby reducing patient trauma. The preference for minimally invasive procedures is rising because both patients and medical professionals favor interventions that shorten recovery periods, diminish the likelihood of complications, and enhance general well-being. Uterine fibroid embolization devices facilitate such procedures by providing accurate and potent treatment for fibroids, leading to better patient results and greater procedural effectiveness. As an illustration, in January 2025, data from AOS Open, a US-based medical journal, indicated that the proportion of minimally invasive surgeries performed in hospitals equipped with robotic-assisted systems increased to 65.8% in 2025, marking an ascent from 60.5% in 2022. Consequently, the expanding need for minimally invasive surgeries is a key factor propelling the development of the uterine fibroid embolization device market.

How Is The Uterine Fibroid Embolization Device Market Divided Into Its Major Segments?

The uterine fibroid embolization device market covered in this report is segmented –

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Subsegments:

1) By Surgical Techniques: Open Surgery, Myomectomy

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)

How Are Trends Transforming The Uterine Fibroid Embolization Device Market Landscape?

Leading companies in the uterine fibroid embolization device market are creating advanced products, such as Minimally invasive fibroid management software, to boost the accuracy and effectiveness of uterine fibroid treatment. This software is an advanced digital platform designed to assist clinicians in the planning, guidance, and execution of minimally invasive procedures for uterine fibroids, thereby enhancing procedural precision, safety, and overall patient outcomes. For example, in September 2024, Gynesonics, a US–based medical device company specializing in minimally invasive gynecologic treatments, introduced SMART OS 2.4 software for its Sonata System to better manage uterine fibroids. SMART OS 2.4 enhances the proprietary SMART Guide by reducing the smallest ablation zone size from 2.0 × 1.3 cm to 1.6 × 1.2 cm, lowering ablation volume by 38%, and refining the Thermal Safety Border for smaller fibroids. These improvements enable more accurate, controlled treatments while preserving healthy uterine tissue, which enhances both procedural efficiency and patient outcomes.

Who Are The Prominent Organizations Shaping The Uterine Fibroid Embolization Device Market?

Major companies operating in the uterine fibroid embolization device market are Johnson and Johnson Pvt Ltd., Medtronic plc., Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Ethicon Inc., Hologic Inc., CooperSurgical Inc., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., Hironic Co.Ltd, Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC

Read the full uterine fibroid embolization device market report here:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

What Are The Top-Performing Regions Within The Uterine Fibroid Embolization Device Market?

North America was the largest region in the uterine fibroid embolization device market in 2025. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Uterine Fibroid Embolization Device Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp

Browse Through More Reports Similar to the Global Uterine Fibroid Embolization Device Market 2026, By The Business Research Company

Uterine Fibroids Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

Uterine Fibroids Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

Tumor Embolization Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795